Circle Cardiovascular Imaging Announces Partnership with DiA Imaging Analysis

Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd. have announced a multi-year partnership that leverages the companies’ synergies in cardiac AI and data analytics.

As a global leader in cardiovascular imaging reading and reporting for Cardiac MR and Cardiac CT, the company has now expanded its rich product offering to a complete cardiovascular imaging portfolio, with the addition of DiA’s FDA-cleared and CE-marked LVivo™ Toolbox – a line of innovative AI-based cardiac ultrasound solutions. This collaboration will deliver expanded state-of-the-art multi-modality imaging solutions to Circle Cardiovascular Imaging’s  customers, while providing new opportunities for physicians, patients, and hospitals worldwide.

“By adding DiA’s solutions, Circle Cardiovascular Imaging is broadening its extensive portfolio of cardiovascular MR and CT, to include ultrasound imaging functionality, offerings that are unparalleled in the market,” said Greg Ogrodnick, CEO of Circle Cardiovascular Imaging.

The company will offer its customers DiA’s LVivo Toolbox, as set of cardiac ultrasound AI solutions which will include LVivo Seamless™ – a unique system that runs “behind the scenes,” automatically selecting the optimal cardiac ultrasound views and generating automated quantifications and indications of both left and right ventricles. The system then immediately extracts these results to the echo reports.

The solutions of both companies are vendor-neutral, running on any scanner, and they can easily integrate into hospital and enterprise sites, with deployments that work with any IT infrastructure.

“Joining forces with Circle Cardiovascular Imaging will accelerate our mission to rapidly deploy health providers with our most advanced and most accurate cardiac ultrasound AI solutions, which will simplify workflows and improve patient outcomes,” said Hila Goldman-Aslan, CEO of DiA Imaging Analysis.

DiA will spotlight its AI-enabled solutions across its imaging portfolio at the upcoming American Society of Echocardiography (ASE) 2021 virtual event (June 18-21, 2021).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version